iOmx Therapeutics Initiates Phase Ib with OMX-0407
August 22, 2024 04:00 ET
|
iOmx Therapeutics AG
Data from the successful Phase Ia dose escalation study showed that OMX-0407 monotherapy demonstrated a favorable safety profile and signs of anti-tumor activity, with one durable complete response in...
iOmx Therapeutics to Present Target Discovery Platform Myeloid iOTarg™ and New Data on SIK Checkpoint Inhibitor OMX-0407 at AACR 2023
March 15, 2023 10:30 ET
|
iOmx Therapeutics AG
Discovery of novel immune checkpoints in the tumor microenvironment with iOTarg™ screening platformPredictive biomarker signature for lead product candidate OMX-0407 MUNICH, Germany, March 15, 2023 ...
iOmx to Present New Pre-Clinical Data on SIK3 Checkpoint Inhibitor OMX-0407 at AACR 2022
April 07, 2022 04:00 ET
|
iOmx Therapeutics AG
MARTINSRIED / MUNICH, Germany, April 07, 2022 (GLOBE NEWSWIRE) -- iOmx Therapeutics AG (iOmx), a biopharmaceutical company developing cancer therapeutics based on next-generation immune checkpoint...